Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) has dosed the first participant in Calliope, a randomized, double‑blind, placebo‑controlled Phase 2 trial of TP‑05 (lotilaner), an investigational oral tablet…
March 31, 2026
Virax Biolabs Secures ISO Quality Milestones to Advance Long COVID and PAIS Diagnostic Strategy
Virax Biolabs Group Limited (NASDAQ: VRAX) announced that its UK subsidiary has obtained ISO 13485:2016 and ISO 9001:2015 certification for its quality management system, issued by…
Noah Labs has secured FDA Breakthrough Device designation for its AI voice-based heart failure monitoring software, positioning the company as an emerging player in the…
March 25, 2026
Corcept Therapeutics Soars as FDA Greenlights Relacorilant for Hard‑to‑Treat Ovarian Cancer
Corcept Therapeutics Inc. (NASDAQ: CORT) stock is surging after the FDA approved its cancer drug relacorilant in combination with nab‑paclitaxel for adults with platinum‑resistant ovarian…
March 23, 2026
Lexicon Pharmaceuticals and Novo Nordisk Kick Off Phase 1 Study for Oral Obesity Drug LX9851
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) and Novo Nordisk A/S have taken a significant step forward in the fight against obesity and metabolic disorders. Today, the…
March 20, 2026
Serina Therapeutics Secures $15 Million in Private Placement to Advance Parkinson’s Therapy
Serina Therapeutics, Inc. (NYSE American: SER), a clinical-stage biotech company, has reached a key milestone in its push to transform Parkinson’s treatment. The company finalized…
March 10, 2026
MiNK Therapeutics Partners with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers
MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company developing invariant natural killer T (iNKT) cell therapies, has entered a strategic collaboration with C-Further to advance…
PepGen Inc. (NASDAQ:PEPG) saw its shares plummet by 26% in after-hours trading on Wednesday, following the U.S. Food and Drug Administration’s decision to impose a…
Market Reaction to Capital Raise MAIA Biotechnology (NYSE: MAIA) experienced a significant market correction in early Tuesday trading. The drug developer saw its stock…
Generate Biomedicines recently made a striking entry into the public markets, raising $400 million through its initial listing—an event that has captured investor attention and…
February 26, 2026
PMV Pharma Publishes First-in-Human Rezatapopt Data in New England Journal of Medicine
PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) announced that first-in-human clinical data for its lead oncology candidate, rezatapopt, were published in the New England Journal of Medicine….
Shares of Palvella Therapeutics (NASDAQ: PVLA) surged 15% Tuesday after the company reported positive topline results from its Phase 3 SELVA clinical trial evaluating QTORIN™…